What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

Eli Lilly (LLY) is strategically diversifying beyond GLP-1 drugs through M&A, including the recent $1.3 billion acquisition of Verve Therapeutics (VERV) to add gene therapies for heart disease. This marks LLY's third deal in 2025, following acquisitions in oncology and neuroscience, reflecting a broader trend of increased M&A activity in the pharma/biotech sector as companies seek portfolio expansion; despite this, LLY's 2025 and 2026 earnings estimates have seen slight declines over the past 60 days.

Analysis

Eli Lilly is actively pursuing strategic diversification beyond its highly successful GLP-1 franchise through a series of targeted M&A deals in 2025, highlighted by its recent $1.3 billion agreement to acquire Verve Therapeutics, adding gene therapies like VERVE-102 for heart disease to its pipeline. This acquisition is LLY's third this year, following a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug STX-478 and a $1 billion agreement for SiteOne Therapeutics' non-opioid pain candidate STC-004, collectively expanding LLY's focus into cardiovascular, oncology, and neuroscience. This proactive M&A strategy mirrors an accelerating trend within the pharma/biotech sector, where major players are leveraging substantial cash reserves to broaden portfolios and innovate pipelines amidst tariff threats and investor pressure for diversification. While Eli Lilly's tirzepatide injections, Mounjaro and Zepbound, exhibit robust sales growth and challenge Novo Nordisk's established products, the company's stock performance (up 1.7% year-to-date, outperforming the industry's 1.2% decline) is juxtaposed with a high forward P/E ratio of 30.06—though below its five-year mean of 34.54—and recent downward revisions to its 2025 and 2026 earnings per share estimates, with 2025 EPS estimates declining from $23.06 to $21.95 and 2026 estimates from $31.15 to $30.91 over the past 60 days.

Key Decisions for Investors

• Investors should closely monitor the integration progress of Verve, Scorpion, and SiteOne Therapeutics, and subsequent development milestones within these newly acquired cardiovascular, oncology, and neuroscience pipelines, as these are crucial for validating Eli Lilly's long-term diversification strategy.
• Careful consideration should be given to Eli Lilly's current valuation, with a forward P/E of 30.06, in light of the recent downward revisions to 2025 and 2026 earnings estimates, balancing this against the strong performance of its GLP-1 franchise and the stock's outperformance.
• It is prudent to assess the potential for these strategic acquisitions to generate future growth and mitigate risks associated with over-reliance on the GLP-1 market, aligning with the company's efforts to build a more diversified revenue base.